Based on the “diabesity” phenotype of mouse models of brain-specific PTPN11 disruption and SHP2’s functions in leptin signaling and energy balance regulation, it has been initially proposed that SHP2 activators could represent interesting therapeutic approaches to alleviate obesity-associated insulin resistance [41,42,68,84]. This evidence concerns the gene LEP and obesity disorder.